FiercePharma1d
Pfizer doubles down with its 2nd FDA hemophilia approval in 6 months
Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...
FiercePharma1d
Thermo Fisher plant in North Carolina flagged for contamination, air bubble issues in FDA inspection
Thermo Fisher Scientific is responsible for helping to produce some of the hottest drugs on the market, including Novo ...
FiercePharma2d
Pfizer targets broad Talzenna approval in prostate cancer as trial meets patient survival goal
In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate ...
FiercePharma1d
Lilly's manufacturing splurge continues with $200M expansion in China
Lilly has earmarked $200 million for the upgrade, a company spokesperson confirmed to Fierce Pharma. The new project will ...
FiercePharma1d
Sanofi’s Dulcolax crowns ‘Pooping Princesses’ to fight constipation-causing stigma among girls and women
A new campaign from Opella, Sanofi’s consumer health unit, is a royal flush. | A new campaign from Opella, Sanofi’s consumer ...
FiercePharma1d
Patients say drug ads help find and manage health conditions—and docs are won over too
The survey suggests ads can improve health management. Almost half of patients said ads help them make informed decisions ...
FiercePharma1d
Sanofi enters talks with private equity firm to sell controlling stake in consumer health unit Opella
With reports swirling about potential interest in Sanofi’s consumer health business, the French pharma has confirmed that a ...
FiercePharma2d
Novartis freed from Swiss antitrust probe over Cosentyx patent strategy
Two years after raiding the offices of Novartis, Switzerland’s Competition Commission (COMCO) has dropped its investigation ...
FiercePharma2d
Activist investor Starboard accuses Pfizer of strong-arming former execs into backing CEO Bourla ahead of strategy meeting
Pfizer’s situation with activist investor Starboard Value is already getting messy. | After initially supporting a meeting ...
FiercePharma2d
Roche burnishes breast cancer portfolio with FDA approval for Itovebi, a threat to Novartis and AZ
As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a ...
FiercePharma1d
A revival in neuro therapeutics
The neuroscience sector has seen a surge in investment over the past year, leading to breakthroughs and high-stakes dea | ...
FiercePharma2d
B. Braun's Florida facility largely unscathed as Hurricane Milton threatens to further upend supplies of critical IV fluids
As Hurricane Milton made landfall in Florida Wednesday night, drugmakers, regulators, hospitals and health agencies alike ...